Tag Archives: MEQ

PR Newswire

DIGITAL THERAPEUTICS STARTUP RESPIREE™ ANNOUNCES RESIDENCY AT JLABS @ SHANGHAI

Leave a comment

SINGAPORE, April 10, 2023 /PRNewswire/ — Respiree announced today that it has become a resident of Johnson & Johnson Innovation – JLABS @ Shanghai (‘JLABS’)[1] from February 21, 2023 , in order to expand its footprint with the goal of deepening its relationships and networks within the pharma and life science sector.

Respiree’s team at JLABS will focus on utilizing the iRIS One decentralized clinical trials platform with the aim to optimize drug trials and discover newer lung and cardiac digital biomarkers. Respiree’s team also aims to extend development of its novel digital therapeutics pipeline to incorporate real-world pharma evidence.

“We are very proud and excited to be joining the JLABS ecosystem. We hope to enhance the iRIS One clinical trials platform.  Through our expanded connectivity we also hope to further develop our digital therapeutics pipeline with the ultimate aim of enabling patients to access better treatments faster,” said Respiree’s CEO and Founder Dr Gurpreet Singh.

Respiree received the 510(k) clearance for its RS001 Cardio-respiratory wearable from the United States Food and Drug Administration (FDA) on 8 March 2023.

[1] Johnson & Johnson Innovation

About Respiree

Respiree is a digital therapeutics company providing personalized healthcare services for cardio-pulmonary disease management using a combination of proprietary breath-cardio sensors, AI and workflow integrated UIUX. Respiree is deployed internationally. Respiree’s iRIS One clinical trials platform is CE marked, approved for use in Australia by the Therapeutics Goods Administration and just received 510(k) clearance for its RS001 Cardio-respiratory wearable from the United States Food and Drug Administration.

PR Newswire

Picarro Cavity Ring-Down Spectroscopy Successfully Validated Under EPA’s OTM-47 to Measure Ethylene Oxide Emissions in Real-Time from Stationary Sources

Leave a comment

SANTA CLARA, Calif., April 5, 2023 /PRNewswire/ — Picarro, Inc. today announced the successful validation and use of the company’s Cavity Ring-Down Spectroscopy (CRDS) under Other Test Method 47 (OTM-47) as published by the Environmental Protection Agency (EPA) on March 23, 2023. The method describes the measurement of ethylene oxide (EtO or EO) emissions from stationary sources by CRDS. OTM-47 represents the first EtO specific real-time stack test method and will provide the industry with a reliable technique for demonstrating regulatory compliance.

CRDS is a highly sensitive analytical technology that can accurately measure trace levels of EtO emissions from source, stack, and ambient applications. The development of OTM-47 was conducted by third-party stack testing company, CleanAir Engineering, using multiple commercially available Picarro instruments, and through site-specific requests for the use of CRDS in performance testing at commercial sterilization facilities. Data gathered through EPA Method 301 validation of OTM-47 demonstrates that Picarro’s CRDS is a reliable and robust technology that can be used as an alternative to less precise technology-based methods such as optically enhanced Fourier Transform Infrared Spectroscopy (OE-FTIR), Gas Chromatography (GC), and passive techniques.

The successful validation of this method reaffirms Picarro’s ability to deliver accurate and reliable testing solutions to medical device and contract sterilization customers and chemical plants. Many incumbent technologies are complicated, expensive to maintain, and require large amounts of downtime due to frequent maintenance. Picarro CRDS operates by measuring the decay rate of light inside of a robust optical cavity using a coherent light source making its systems less susceptible to interference when measuring target gases such as EtO.

“We are excited to see the successful validation of CRDS under Other Test Method 47. This method will allow customers emitting ethylene oxide to generate more accurate and defensible data than other technologies, which is critical for ensuring compliance and mitigating regulatory risk,” said Joel Avrunin, Vice President of Environmental at Picarro.

About Picarro
Picarro is a leading provider of Cavity Ring-Down Spectroscopy (CRDS)-based, real-time monitoring solutions that offer advanced detection and data analytics technology. Picarro’s suite of systems provides end-to-end visibility with monitoring systems for stacks, indoor air, and fencelines that are supported by a team of experienced and highly qualified professionals who are committed to providing turn-key solutions to customers.  With more than 25 years of expertise and thousands of customers in nearly 100 countries, Picarro is a trusted and reliable partner in ensuring compliance with regulations and environmental standards. For more information, visit www.picarro.com.

Media Contacts:
Jake Thill
Director, Marketing Communications
Picarro, Inc.
jthill@picarro.com

Source: Picarro, Inc.

PR Newswire

Martech platform Ortto celebrates record growth on the anniversary of its rebrand

Leave a comment

The unified customer data, analytics, and marketing automation platform Ortto, formerly Autopilot, continues to see double-digit monthly growth a year on from its rebrand. The martech company now has more than 3,000 customers globally and was recognized in 49 categories in G2’s biannual report.

SYDNEY, March 8, 2023 /PRNewswire/ — Ortto, which started as Autopilot Journeys in 2015, rebranded in early 2022 following the launch of a revolutionary new platform that allows marketers to effortlessly connect previously siloed data sources to get a complete view of their customers. Marketers can analyze and operationalize this data without the need for specialized support, enabling them to deliver personalized customer journeys at scale, increasing the impact of their campaigns with powerful event-based triggers and AI-content optimization. In the year since the rebrand, Ortto’s users have built some 5,000 journeys and sent more than 210 million emails to their customers, contributing to the  company’s sustained 16% month-on-month growth.

Ortto helps data-driven marketers easily build powerful reports to understand what’s working and make decisions with confidence. Dashboards allow teams to pin key reports to a shared space so they never lose sight of key metrics.
Ortto helps data-driven marketers easily build powerful reports to understand what’s working and make decisions with confidence. Dashboards allow teams to pin key reports to a shared space so they never lose sight of key metrics.

  • The powerful platform received the ‘High Performer’ badge in 11 categories in the G2 Winter 2023 reports, including marketing automation and marketing platform, across multiple regions (APAC, ANZ, Europe, UK, etc.)
  • Ortto was also awarded the ‘Best estimated ROI’ badge and the ‘Easiest to use’ badge in the customer journey mapping categories, as well as the ‘Users Love Us’ badge.
  • The platform was also ranked number one for data personalization by SoftwareReviews.

Customer, Mica Shtewi, Tech Manager at Pattern, comments:

“When you’re moving into a world we’re moving into, you have so many data sources that you’re trying to bring together and various communications to get clients moving through the sales process. We needed something flexible that works and had a robust integration with Salesforce, and with Ortto we can target people the way we want to target them.”

Visually design journeys that automate personalized messages and trigger actions across the customer lifecycle with Ortto.
Visually design journeys that automate personalized messages and trigger actions across the customer lifecycle with Ortto.

Michael Sharkey, CEO and co-founder of Ortto, comments:

“Everyone recognizes the importance of data in building better, more personalized customer experiences, but the problem is, for many businesses, this data is located across a number of different tools and isn’t easily accessible to marketers. That’s why we rebuilt our platform to make it easy to bring all of that data together in one place and remove the barriers to entry, so marketers have ready access to the data they need without having to lodge a ticket or learn SQL. The response to the new platform has been incredible – not only from our Autopilot customers, who are realizing new value through Ortto, but also from new customers who have come on board in the past year.”

About Ortto

Ortto, the world’s first complete marketing automation, AI and analytics platform, empowers marketers to act with confidence and increase their impact on revenue. By combining three powerful tools into one intuitive platform, teams finally benefit from their customer data, messaging, and analytics working together.

Sophisticated yet easy to use, more than 3,000 customers trust Ortto to understand their impact, discover their next marketing opportunity, and continuously iterate to deliver great customer experiences at scale. Learn more at: www.ortto.com 

Launched in 2015, Ortto’s team is located in Australia, Europe and the US. To date, the company has raised $35M in venture funding from backers including Blackbird, Rembrandt and Salesforce Ventures.

Source: Ortto, Inc.

PR Newswire

US proteomics sector set for shake-up as new IonOpticks tech unveiled

Leave a comment

IonOpticks to introduce the TS, a fully integrated column heating and interface solution for Thermo Scientific users

MELBOURNE, Australia, March 3, 2023 /PRNewswire/ — IonOpticks, a producer of high-performance chromatography solutions for the global research community, will introduce the new TS product range to the US market at US HUPO’s (US Human Proteome Organization) 19th Annual Conference in Chicago on 4-8th March, a renowned event attended by proteomics experts from around the globe.

IonOpticks’ new TS range was developed as a simple plug-and-play, fully integrated heating and source solution for Thermo Scientific mass spectrometer users, who have previously only been able to access the results achievable with IonOpticks Aurora Series columns by creating their own interface – a costly and difficult alternative.

“Researchers can now easily unlock the full potential of their mass specs through the launch of our new TS range. Thermo Orbitraps have been cited in roughly 85% of all publications related to proteomics in the last decade, so we’re excited to make our famed Aurora Series products easily accessible to this significant portion of the mass spec community,” says Xavier Perronnet, Managing Director at IonOpticks.

“We’re excited to be attending US HUPO, to meet with our peers and showcase how the TS, combined with our Aurora Series columns, can provide Thermo mass spec users the ability to supercharge the sensitivity of their existing instruments. Our columns enable researchers to delve deeper into their samples than ever before.” Mr Perronnet continues.

The combination of IonOpticks’ proprietary nanoZero® fittings and integrated emitter with the new TS range removes all pre- and post-column dead volume, maximizing the capacity of the chromatographic packed bed to separate samples. Further, the heating solution in the TS is reusable which saves users both time and money while reducing unnecessary waste.

The TS range was developed following the paradigm-shifting release of the Aurora Frontier – the first ever column to routinely generate over 10,000 protein identifications on a Thermo mass spectrometer – from a single sample and single species.

“The results that have been achieved with our Aurora Frontier have been outstanding and we’re proud to continue to develop products that enable us to ensure access to these gains is equal for all researchers,” says Dr Jarrod Sandow, Head of Product Development at IonOpticks.

“Thermo users continue to be top customers of our products, so we’ve worked hard behind the scenes to ensure these users can easily boost the performance of their existing instruments through a simple all-in-one heating and source integration system. One that requires no complex installation and is ready to use straight out of the box,” Dr Sandow adds.

IonOpticks is committed to ensuring the world’s best chromatography is available to all mass spec users. Alongside the TS, IonOpticks have also launched the SX, a fully integrated column heating and interface solution for SCIEX users.

About IonOpticks

IonOpticks produces high-performance chromatography solutions for the global research community.

We specialise in the development and manufacture of columns for analytical applications in liquid chromatography with mass spectrometry (LC-MS) and high-end proteomics. Our highly reproducible methods provide a unique ability to enhance the sensitivity of mass spectrometry sample analysis, enabling scientists and clinicians to discover more from their samples.

Our team are experts in a broad array of LC-MS platform technologies and are driven by the need to improve chromatographic performance in order to achieve data quality and deep proteome coverage on a whole new scale.

https://ionopticks.com/ / https://www.proteomicssolved.com/

Cision View original content:https://www.prnewswire.com/news-releases/us-proteomics-sector-set-for-shake-up-as-new-ionopticks-tech-unveiled-301760866.html

PR Newswire

Guardant Health to integrate Lunit’s AI-based scoring algorithm for PD-L1 into its portfolio to enhance cancer biomarker detection

Leave a comment

  • Powered by Lunit SCOPE PD-L1, the Guardant360 TissueNext PD-L1 test with Guardant Galaxy™ shows improved detection of the biomarker in NSCLC
  • Lunit’s AI solution is the first application in Guardant Galaxy, a suite of AI and other technology tools that enhance Guardant Health’s portfolio of cancer tests

SEOUL, South Korea, Jan. 31, 2023 /PRNewswire/ — Lunit (KRX:328130.KQ), in partnership with leading precision oncology company Guardant Health, today announced the integration of its AI-based PD-L1 scoring algorithm into Guardant’s testing workflow to enhance biomarker detection in the Guardant360 TissueNextTM PD-L1 test for non-small cell lung cancer (NSCLC).

The newly integrated algorithm will enable Guardant to offer augmented biomarker assessment for NSCLC patients through AI-based quantification of tissue samples using a scoring system generated by Lunit SCOPE PD-L1. The enhanced Guardant test is designed to support pathologists in diagnosing PD-L1 status with higher accuracy and efficiency. Through the AI software, the test showed improved detection of PD-L1 by more than 20 percent compared to manual pathologist interpretation in the most challenging cases in NSCLC1.

Lunit SCOPE PD-L1 is a CE-marked AI solution for detecting and analyzing PD-L1, a cancer biomarker. The solution may assist pathologists by minimizing interpretation discrepancy and allowing better prediction of treatment outcomes for non-small cell lung cancer (NSCLC) patients, as demonstrated in study findings published in the European Journal of Cancer.

Lunit SCOPE PD-L1’s integration with the Guardant360 TissueNext PD-L1 test is the first application in Guardant Galaxy, Guardant Health’s suite of technology applications developed internally and through outside partnerships to enhance the performance and utility of its portfolio of cancer tests.

The two companies have been in partnership since 2021, following a strategic investment from Guardant Health to Lunit.

“We are honored to partner with Guardant Health in leveraging the power of AI and digital pathology to enhance the capabilities of their comprehensive genomic profiling tests for cancer patients,” said Brandon Suh, CEO of Lunit. “The development of the AI-supported scoring algorithm for the Guardant360 TissueNext PD-L1 test is a great example of using advanced medical image analytics to enhance precision diagnostics in lung cancer and help doctors find the right treatment for the right patients.”

“With Guardant Galaxy, we are now accessing the most advanced AI techniques and the latest complementary technologies from leading companies in cancer diagnostics to enhance the capabilities of our tests and provide oncologists and researchers with precise and actionable information,” said Helmy Eltoukhy, co-CEO of Guardant Health. “The digital pathology solution from Lunit has already demonstrated the power of AI to help improve detection of PD-L1 in certain cases of non-small cell lung cancer. We believe it has the potential to contribute much more broadly to advances in identifying cancer biomarkers and informing treatment decisions.”

About Lunit

With AI, Lunit aims to ‘conquer cancer,’ one of the leading causes of death worldwide. Lunit is an AI software company devoted to developing AI solutions for precision diagnostics and therapeutics, to find the right diagnosis at the right cost, and the right treatment for the right patients. Lunit, a portmanteau of ‘learning unit,’ is a deep learning-based medical AI company devoted to developing advanced medical image analytics and data-driven imaging biomarkers via cutting-edge technology.

Founded in 2013, Lunit has been acknowledged around the world for its advanced, state-of-the-art technology and its application in medical images. Its technology has been recognized at international AI competitions surpassing top companies like Google, IBM, and Microsoft. As a medical AI company with a focus on clinical evidence, the company’s findings are presented in major peer-reviewed journals such as the Journal of Clinical Oncology and JAMA Network Open, and global conferences including ASCO and AACR. After receiving FDA clearance and the CE Mark, Lunit INSIGHT CXR and MMG are clinically used in approximately 1,000 hospitals and medical institutions across more than 40 countries. Lunit is headquartered in Seoul, South Korea with offices and representatives around the world.

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. Lunit SCOPE PD-L1 is CE marked in Europe and has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantNFINITY® tests for advanced stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the ShieldTM test, aims to address the needs of individuals eligible for cancer screening.

References

1. Sangjoon Choi et al. Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response, European Journal of Cancer 2022, Volume 170, 17-26

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/guardant-health-to-integrate-lunits-ai-based-scoring-algorithm-for-pd-l1-into-its-portfolio-to-enhance-cancer-biomarker-detection-301734438.html

PR Newswire

VUNO Showcases their AI Solutions and Research Results at RSNA 2022

Leave a comment

SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ — VUNO Inc., a leading South Korean artificial intelligence (AI) developer, announced that it will participate in the Radiological Society of North America 2022 (RSNA 2022). This year, VUNO will focus on highlighting how their breakthrough AI technology drives real world clinical value across radiological workflows and how their solutions contribute to improving quality of patient care. The exhibition will be held at McCormick Place in Chicago, Illinois from Nov. 27-Dec.1, 2022.

Meet VUNO at RSNA 2022
Meet VUNO at RSNA 2022

VUNO will showcase four medical artificial intelligence solutions: VUNO Med®-DeepBrain®, VUNO Med®–LungCT AITM, VUNO Med®-Chest X-rayTM and VUNO Med®-BoneAgeTM, which can all be seamlessly integrated with PACS (Picture Archiving and Communication System), EMR (Electronic Medical Record) systems, and medical device hardware. A simulation reading room will be set up at VUNO’s booth, so visitors can experience how VUNO Med® solutions integrate with PACS. Visitors will also have the chance to demo the four medical artificial intelligence solutions as standalone products.

VUNO will present two research achievements about VUNO Med®-DeepBrain®, a medical AI solution that performs brain volumetric and quantitative analysis of cerebral MR images, at a neuroradiology poster session. They delve into how AI algorithms can be used to identify neuroimaging biomarkers and support decision making process in practice. VUNO will discuss an automatic medial temporal lobe atrophy (MTA) score (also known as Scheltens’ scale) prediction algorithm and a white matter hyperintensity (WMH) quantification model accompanying the Fazekas scale estimation.

Yeha Lee, CEO of VUNO said, “Through participating in RSNA 2022, VUNO will introduce various clinical research achievements to the global radiology community and demonstrate the capabilities and impact of our AI technology,” adding “we plan to expand our partnerships with overseas partner companies and medical institutions by offering the opportunity for attendees to directly experience VUNO Med® solutions.”

About VUNO Inc.

VUNO is a leading AI medical software company that develops deep learning-based AI medical solutions in the fields of medical imaging, bio-signal and digital pathology. We strive to optimize and improve clinical workflows, while empowering medical practitioners to make better diagnostic decisions faster and more accurately – providing quality patient care and treatment planning. For more information, visit www.vuno.co.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vuno-showcases-their-ai-solutions-and-research-results-at-rsna-2022-301687126.html

Source: VUNO Inc.

PR Newswire

ICP DAS – BMP to partake in the COMPAMED 2022, Germany for the first time

Leave a comment

HSINCHU, Nov. 1, 2022 /PRNewswire/ — ICP DAS – BMP (Biomedical Polymers), a Taiwan medical TPU (thermoplastic polyurethane) supplier, will exhibit TPU pellets with 50% tungsten content (W50) for the first time in the COMPAMED 2022, Germany. The exhibition – a melting pot for high-tech solutions in the medical technology sector – takes place in DÜSSELDORF from 14 to 17 November.

ICP DAS - BMP to partake in the COMPAMED 2022, Germany
ICP DAS – BMP to partake in the COMPAMED 2022, Germany

ICP DAS – BMP will showcase three series of highly stable medical-grade TPU pellets, namely, Alithane™ (ALP series), Durathane™ (ALC series), and Arothane™ (ARP series). This year, ICP DAS – BMP unveils a new range of pellets with a tungsten content of 30% (W30) and 50% (W50), respectively. As we advance, ICP DAS – BMP plans to develop pellets with 70% tungsten content (W70) and a new ARP-CHDM series in 2023.

All medical-grade TPU pellets by ICP DAS – BMP are 100% made in Taiwan and have superb biocompatibility, hydrolytic & chemical resistance, mechanical properties, and radiodensity; they can be customized and color-matched. To provide customers with the best service, ICP DAS – BMP offers shorter lead times and accepts smaller quantity orders.

Applications of medical-grade TPU pellets range from cancer treatment and urology devices to retainers, etc. Shortly after being established, ICP DAS – BMP achieves outstanding results domestically and internationally. Medical device manufacturers from South Korea, Israel, and France have chosen ICP DAS – BMP’s trustworthy and high-quality TPUs.

Visit ICP DAS – BMP’s booth at Hall 08B, Booth 8BC17-2, from 14 to 17 November 2022, and learn more about the upcoming ARP-CHDM series.

About ICP DAS – BMP

In response to the growing demand for TPUs in medical applications, in 2018, ICP DAS established a new business unit to develop and produce medical-grade TPUs, ICP DAS – BMP. The company has obtained ISO 13485 certification for its raw material warehouses and production lines.

ICP DAS – BMP has its own laboratories for polymerization, physical properties analysis, and cytotoxicity testing. All the TPUs supplied by ICP DAS – BMP are USP Class VI certified and compliant with the ISO 10993 international standard. Materials have passed skin sensitization and cytotoxicity tests according to ISO 10993-5 and ISO 10993-10. These enable ICP DAS – BMP to guarantee biocompatibility for medical device manufacturers.

For more details, please visit our website: https://bmp.icpdas.com/

For TPU products, solutions, and inquiries, contact us directly: sales_bmp@icpdas.com

Source: ICP DAS Co., Ltd.

PR Newswire

World Stroke Organization Tackle Gaps in Access to Quality Stroke Care

Leave a comment

GENEVA, Switzerland, Oct. 28, 2022 /PRNewswire/ — On World Stroke Day (29th Oct), the World Stroke Organization has announced the launch of a new program that aims to drive access to quality acute stroke care and save lives around the world.

What happens in the minutes after someone has a #stroke? They start to lose crucial brain tissue that contains memories, language and personality. Knowing the symptoms and acting FAST can save that person’s life.Learn the signs, Say it’s a stroke. Save #Precioustime
What happens in the minutes after someone has a #stroke? They start to lose crucial brain tissue that contains memories, language and personality. Knowing the symptoms and acting FAST can save that person’s life.Learn the signs, Say it’s a stroke. Save #Precioustime

The WSO Stroke Certification initiative is a strategic response to the results of a WHO-WSO survey which found that less than half (49%) of countries could provide comprehensive evidence-based acute stroke care. The survey also identified a huge gap in provision of care between high- and low- and middle-income countries. While 91% of high-income countries were able to provide access to specialist stroke unit care, the number was just 8% in low-income countries. 

Two of the fundamental markers of quality acute stroke care are the provision of thrombolysis (the removal of blood clots using intravenous medication) and thrombectomy (the removal of blood clots by keyhole surgery). Research published by WSO found global rates of access to these treatments stand at 46% and 30% respectively.

‘One in four of us will have a stroke in our lifetime, yet the majority of people globally lack access to effective treatment and stroke center care. On top of this, a lack of effective global prevention strategies has led us to a place where stroke is the second leading cause of death and the third leading cause of disability worldwide, with a soaring human and economic cost,’ said WSO President Professor Marc Fisher. Incoming WSO President and leading Brazilian neurologist, Professor Sheila Martins added: ‘We have the knowledge and tools that could save millions of lives and hundreds of millions of dollars. Delivering quality stroke care is not just the right thing to do, it’s the smart thing to do.’

WSO’s Global Stroke Guidelines and Action Plan aim to help institutions and governments implement evidence-based criteria and standards for care developed by WSO. Initially targeting hospitals in middle-income countries, the program will be launched on Nov 1st with the primary aim of growing the global network of accredited stroke care providers.

Stroke is a leading cause of death and disability worldwide. On World Stroke Day the public, health care professionals, stroke survivors, politicians and industry leaders will come together to raise awareness of stroke symptoms and the importance of timely treatment.  

The public can follow the campaign on social media using #Precioustime and help raise awareness by sharing a clock selfie or participating in the strokespotter.org online game challenge.

Notes to Editors

I. The World Stroke Organization is the only global body solely focused on stroke. With around 3000 individual and 100 society members, spanning every global region, we represent over 55,000 stroke specialists in clinical research and support services. WSO is in official relations with WHO and has UN consultative status.
II. The WSO Stroke Certification program builds on the WSO-SIEVC Certification program in Latin America and the Caribbean https://www.world-stroke.org/news-and-blog/news/wso-siecv-certification-of-stroke-centers-in-latin-america-and-caribbean
III. State of stroke services across the globe https://journals.sagepub.com/doi/abs/10.1177/17474930211019568 
IV. WSO Global Stoke Factsheet https://www.world-stroke.org/publications-and-resources/resources/global-stroke-fact-sheet 
V. World Stroke Day website www.worldstrokecampaign.org

Contacts:

Anita Wiseman,
Campaign & Partnerships Manager, WSO
campaign@world-stroke.org
+447940029444

Knowing the symptoms and signs of a #stroke and acting #FAST can save a person’s life and all the things that make them unique.Learn the signs, Say it’s a stroke. Save #Precioustime
Knowing the symptoms and signs of a #stroke and acting #FAST can save a person’s life and all the things that make them unique.Learn the signs, Say it’s a stroke. Save #Precioustime
PR Newswire

Vieworks Wins FDA Approval for Its Newest VIVIX-S F series

Leave a comment

ANYANG, South Korea, Aug. 5, 2022 /PRNewswire/ — Vieworks, a leading digital X-ray imaging solution provider based in South Korea, noted that its newest VIVIX-S F series has been authorized by the US Food and Drug Administration (FDA) last July. Regulatory clearance from the FDA will allow Vieworks to commercialize its new VIVIX-S F series, which is Vieworks’ premium static X-ray DR flat panel detectors equipped with advanced technology and cutting-edge hardware design. The cassette-sized DR detectors are offered in 3 sizes – 25x30cm (VIVIX-S 2530FW), 36x43cm (VIVIX-S 3643FW), and 43x43cm (VIVIX-S 4343FW).

VIVIX-S F series
VIVIX-S F series

1. FINEST Image Quality

  • High resolution images with 99µm pixel pitch
  • Semi-dynamic feature (multi-frame mode)
  • Anatomy-based image enhancement with photon-understanding AI solution
  • Advanced image processing technology (VXvue, Software-based Scatter Correction)

2. FINEST Durability

  • Unbreakable glass-free TFT (flexible TFT)
  • Excellent durability (1.5m drop tested, 400kg load limit)
  • IP67 water and dust resistance
  • Wider operating temperature

3. FINEST Usability

  • Lighter weight for greater portability
  • Convenient charging (wireless charging, separate battery charger, USB-C type, magnetic tether, cradle)
  • Long lasting battery life (16 hours with two batteries, hot-swap mode)
  • Easy usage with user-friendly functions (Fast and convenient detector sharing by NFC, OLED status screen)

Source: Vieworks Co., Ltd.

PR Newswire

Vela Diagnostics Develops PCR-based Test for Detecting Monkeypox Virus

Leave a comment

SINGAPORE, July 26, 2022 /PRNewswire/ —  Vela Diagnostics announced that it has developed a PCR test kit to detect the monkeypox virus (MPXV), for research use only (RUO).

The ViroKey® MPXV PCR Test allows for the prompt, in vitro detection of MPXV DNA from human skin lesion specimens. It is compatible with common real-time PCR cyclers, such as the Rotor-Gene Q and Applied Biosystems 7500 series platforms. In silico testing shows that the assay is specific for MPXV and has no cross-reactivity with other orthopoxviruses.

“We worked closely with our customers to develop a test that is specifically designed to meet their requirements, making sure that they have a monkeypox-specific assay, with maximum flexibility to choose between manual and automated workflows depending on the number of samples they receive,” said Dr Charlie Lee, Head of Research and Development at Vela Diagnostics.

The monkeypox outbreak has been declared a global health emergency by the World Health Organization (WHO), with over 16,000 cases worldwide. The mode of transmission is thought to be close, sustained physical contact with other people who have monkeypox. The WHO has requested for all countries to provide testing for any individuals that meet the suspected case definition, and to immediately notify it in the case of positive laboratory results.

“Throughout the COVID-19 pandemic, we have worked closely with various testing labs across the globe. We responded quickly to the monkeypox epidemic by allowing research partners and laboratories to offer timely and accurate monkeypox testing,” said Sam Dajani, CEO of Vela Diagnostics and Chairman of the Board. “We have already released the first few batches of kits, and they are being evaluated by our customers globally. We are committed to increasing testing capacity of monkeypox in hopes of containing the spread of the virus.”

For more information; including the IFU, please contact us.

About Vela Diagnostics

Vela Diagnostics is a leading provider for integrated IVD system solutions, from sample to result. VELA’s test solutions utilize the automated SentosaTM platform, providing the unique ability to leverage one system for NGS and PCR testing in infectious disease and oncology.

All Sentosa products listed above are by Vela Diagnostics. For more information, visit www.veladx.com. All other product names, trademarks and logos are the property of their respective owners.

Cision View original content:https://www.prnewswire.com/news-releases/vela-diagnostics-develops-pcr-based-test-for-detecting-monkeypox-virus-301593161.html